EBC-46

mechanism

Reactive Oxygen Species and EBC-46: Oxidative Stress Pathways in Tigilanol Tiglate Cell Death

How tigilanol tiglate (EBC-46) elevates intracellular reactive oxygen species, contributing to mitochondrial dysfunction and tumour cell death in preclinical work.

Regulatory

India's FSSAI and EBC-46: How the Nutraceutical Framework Treats Botanical Supplements

How India's FSSAI Nutraceutical Regulations classify botanical supplements like blushwood berry extract — and what consumers and importers should expect.

Human Trials

EBC-46 Trial Adverse Event Profiles: Published Data on Tolerability Across Patient Cohorts

A neutral look at adverse events reported in published Phase I and Phase II EBC-46 trials, including injection-site reactions and what the overall tolerability picture shows.

Regulatory

Swiss Swissmedic and EBC-46: Complementary Medicines Licensing for Blushwood Berry in Switzerland

How Switzerland’s Swissmedic regulates complementary and herbal medicines, and where blushwood berry extract products sit within the Swiss supplement framework.

EBC-46

EBC-46 Supplement Bioavailability: What User Reports Suggest About Absorption

A candid look at what is and isn't known about oral bioavailability of blushwood berry extract, and how to read anecdotal absorption reports from users.

EBC-46

Pollination Ecology of Fontainea picrosperma: Reproductive Biology of the Blushwood Tree

Dioecy, insect pollinators, seed dispersal, and recruitment — the reproductive ecology of F. picrosperma that shapes both cultivation and conservation.

EBC-46

Long-Term Follow-Up: Tigilanol Tiglate Recurrence Rates in Veterinary and Human Trials

What the published long-term follow-up data show for tigilanol tiglate in veterinary and human trials, and why supplement buyers should read it carefully.

EBC-46

Cytolytic Cascade: How EBC-46 Triggers Tumour Cell Membrane Disruption

The cytolytic cascade triggered by tigilanol tiglate — PKC activation, membrane destabilisation, and necrotic cell death — explained from the peer-reviewed literature.

EBC-46

UK MHRA and Botanical Supplements: Where EBC-46 Fits in the UK Regulatory Framework

How the UK MHRA and Food Standards Agency treat EBC-46 supplements: not medicines, regulated as food supplements, with no therapeutic claims permitted.

Consumer Reports

EBC-46 Supplements and Seasonal Wellness: What Users Report About Year-Round Supplementation Patterns

A look at emerging user reports on seasonal supplementation patterns with blushwood berry extract, including how users adjust their routines throughout the year.

Botany

Canopy Light Dynamics and EBC-46 Concentration: How Sunlight Exposure Shapes Blushwood Berry Chemistry

Examining how light availability and canopy position influence tigilanol tiglate concentration in Fontainea picrosperma fruit, with implications for cultivation.

Human Trials

Tumour Microenvironment Remodelling After EBC-46 Injection: What Biopsy Data From Human Trials Reveals

Analysis of published biopsy findings from EBC-46 human trials showing immune infiltration, vascular disruption, and tissue remodelling patterns post-injection.